Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial.

Aún no traducido Aún no traducido
Categoría Estudio primario
RevistaArthritis and rheumatism
Año 2011
Cargando información sobre las referencias
Objective Juvenile localized scleroderma is a chronic progressive fibrotic disorder of the skin that causes permanent disability and aesthetic damage. This study was undertaken to assess the safety and efficacy of methotrexate (MTX) in the treatment of juvenile localized scleroderma. Methods In this double-blind study, patients with active juvenile localized scleroderma were randomized (2:1) to receive oral MTX (15 mg/m
Epistemonikos ID: ffa349e3ed44600b260367c5b4e28c7d53db67b3
First added on: Jan 10, 2019